Recovery of Upper Limb Function in Persons With Spinal Cord Injury: Lead-In Study (MyndMove)

University of British Columbia

Status: Terminated

Conditions: Traumatic Spinal Cord Injuries

Treatments: Device: Myndmove

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02799966

H16-00552

Details and patient eligibility

About

Many individuals with cervical spinal cord injury (SCI) have difficulty using their hands and arms. MyndMove is a non-invasive medical device that uses short, low energy electrical pulses with surface electrodes to cause muscle contractions to produce a full range of reaching and grasping movements, which the patient is unable to perform by him/herself.

By using MyndMove therapy to help the individual move their arms and hands as he/she attempts to carry out typical reaching and grasping movements, the individual improves their ability to perform these tasks voluntarily.

The purpose of this study is to study the effectiveness of MyndMove therapy in improving the ability of individuals to move their arms and hands.

Full description

There is no control group for this study. Participants from both treatment groups:

• Early treatment group = 10 days to 6 months post tSCI and
• Late treatment group = 6 months plus one day post tSCI

will receive one session (60 minutes) of MyndMove therapy, 3 to 5 times per week (only once per day), to gain 20 hours of intervention (total treatment duration will be 4 to 7 weeks).

Each 1 hour session includes therapy for single-arm or bilateral (left and right upper extremities) as clinically indicated for each study participant. Over the course of 20 one hour sessions, participants will progress through the various movement sequences aimed at regaining natural, unassisted voluntary movement in the affected limb(s). The MyndMove therapy will be in addition to the conventional upper limb rehabilitation therapy the participant will be prescribed to undertake at their local institution.

From previous experience, the first signs of function recovery may be expected to emerge two to four weeks after the onset of the MyndMove therapy program. As soon as the participant shows signs of recovery of either the voluntary extension or flexion in a stimulated muscle group, s/he will be encouraged to make an effort to voluntarily produce the movement that was previously facilitated by FES. As the participant demonstrates improved strength and range of motion, the FES for that muscle group will be phased out, and moved to another muscle group that is still paralyzed and needs to be "reactivated". The order in which muscle groups will be sequentially "reactivated" will be patient dependent.

Muscle reactivation milestones will be monitored and recorded during MyndMove therapy. The number of MyndMove treatments required to reach each milestone will be recorded. In addition, the overall time required to reach each milestone will be recorded.

Total duration of study participation, including a follow-up assessment, will be approximately 4 to 5 months.

Enrollment: 9 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Traumatic incomplete (AIS B-D) C4-C7 SCI
2. Early treatment group = 10 days to 6 months (182 days) post tSCI (note it is expected that most ppts will be recruited from this group, while at GF Strong)
3. Late treatment group = initiate treatment on or after 6 months plus one day (183 days+) post tSCI
4. SCIM self-care sub-score ≤ 10
5. Able to understand and follow instructions
6. Able to be in a seated position for a least one hour of upper limb therapy
7. Able to attend the study treatment sessions
8. Able to provide informed consent
9. Men and women of the age of majority in their province or state

Exclusion criteria

1. Previous history of any other neurological disorder or conditions that may affect motor response
2. Upper extremity injury or condition prior to SCI that limits the function of the hand or arm
3. Malignant skin lesion on the affected upper extremity
4. History of seizure disorder not effectively managed by seizure medications
5. An existing electrical stimulation devices (e.g. ICD, Pacemaker, Spinal Stimulation)
6. Rash or open wound at any potential electrode site
7. Denervation of muscles that are targeted by MyndMove
8. Poorly controlled autonomic dysreflexia (as determined by the local site physician)
9. In the judgment of the local site physician, participant has medical complications that may interfere with the execution of the study
10. Botulinum toxin injection into affected upper extremity within 3 months prior to the study start. No botulinum toxin injections during the study treatment and follow up period.
11. Currently enrolled in another upper limb study
12. Enrolled, in the past six months, in a clinical study involving drugs or biologics

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

9 participants in 2 patient groups

Early Treatment Group

Other group

Description:

Initiate treatment with MyndMove device on or after 10 days to 6 months (182 days) post spinal cord injury

Treatment:

Device: Myndmove

Late Treatment Group

Other group

Description:

Initiate treatment with MyndMove device on or after 6 months plus one day (183 days+) post spinal cord injury

Treatment:

Device: Myndmove